Arndt Vogel, Full Professor at Princess Margaret Cancer Centre, shared on X:
“Phase I study of BGB-B2033 (GPC3 x 4-1BB bispecific AB)
Dose optimization and escalation update in advanced HCC:
- ORR: 30%
- manageable safety
- very promising agent, looking forward to see combination with ICI.”
You can also read:
